Medicus Pharma Ltd
- LAST PRICE2.2500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.2100/ 5
- Ask / Lots2.3000/ 6
- Open / Previous Close0.0000 / 2.2500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDCX |
|---|---|---|
| 09:45 ET | 100 | 2.25 |
| 10:35 ET | 200 | 2.25 |
Apr 25, 2024
Canadian Investment Regulatory Organization Trade Resumption - MDCX, from 4:10PM ET on Thursday Apr 25, 2024 by Dow Jones
4:10PM ET on Thursday Apr 25, 2024 by Dow JonesMedicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes, from 3:08PM ET on Thursday Apr 25, 2024 by Dow Jones
3:08PM ET on Thursday Apr 25, 2024 by Dow JonesCanadian Investment Regulatory Organization Trading Halt - MDCX, from 9:17AM ET on Thursday Apr 25, 2024 by Dow Jones
9:17AM ET on Thursday Apr 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Medicus Pharma Ltd | 36.7M | -2.2x | --- |
LSL Pharma Group Inc | 45.9M | 0.0x | --- |
BioNxt Solutions Inc | 43.8M | -5.2x | --- |
Devonian Health Group Inc | 32.9M | -7.2x | --- |
BellRock Brands Inc | 48.9M | -0.6x | --- |
Pharmather Holdings Ltd | 23.4M | -5.4x | --- |
Company Information
Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma.
Contact Information
- Headquarters
- 217 Queen Street West, Suite 401TORONTO, ON, Canada M5V 0R2
- Phone
- 905-681-1925
- Fax
- 905-681-1925
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.2M |
Medicus Pharma Ltd does not pay a dividend. | |
Beta | --- |
EPS | $-1.03 |
Book Value | $-0.06 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
